Geode Capital Management’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.4M | Buy |
801,504
+32,148
| +4% | +$52.9K | ﹤0.01% | 3252 |
|
|
2025
Q4 | $1.34M | Buy |
769,356
+222,609
| +41% | +$490K | ﹤0.01% | 3289 |
|
|
2025
Q3 | $1.28M | Buy |
546,747
+109,198
| +25% | +$209K | ﹤0.01% | 3309 |
|
|
2025
Q2 | $891K | Sell |
437,549
-409,254
| -48% | -$784K | ﹤0.01% | 3364 |
|
|
2025
Q1 | $1.38M | Buy |
846,803
+218,298
| +35% | +$438K | ﹤0.01% | 3189 |
|
|
2024
Q4 | $1.15M | Buy |
628,505
+6,874
| +1% | +$30.4K | ﹤0.01% | 3322 |
|
|
2024
Q3 | $3.59M | Buy |
621,631
+38,833
| +7% | +$320K | ﹤0.01% | 2923 |
|
|
2024
Q2 | $4.71M | Buy |
582,798
+330,195
| +131% | +$3.47M | ﹤0.01% | 2764 |
|
|
2024
Q1 | $3.51M | Buy |
252,603
+13,316
| +6% | +$115K | ﹤0.01% | 2878 |
|
|
2023
Q4 | $1.46M | Buy |
239,287
+10,035
| +4% | +$49.5K | ﹤0.01% | 3203 |
|
|
2023
Q3 | $1.07M | Sell |
229,252
-9,185
| -4% | -$50.7K | ﹤0.01% | 3290 |
|
|
2023
Q2 | $1.28M | Sell |
238,437
-192,961
| -45% | -$1.56M | ﹤0.01% | 3258 |
|
|
2023
Q1 | $4.24M | Buy |
431,398
+23,888
| +6% | +$407K | ﹤0.01% | 2710 |
|
|
2022
Q4 | $7.63M | Buy |
407,510
+24,175
| +6% | +$548K | ﹤0.01% | 2437 |
|
|
2022
Q3 | $7.93M | Buy |
383,335
+53,039
| +16% | +$1.36M | ﹤0.01% | 2400 |
|
|
2022
Q2 | $6.86M | Buy |
330,296
+47,543
| +17% | +$1.34M | ﹤0.01% | 2513 |
|
|
2022
Q1 | $12.2M | Sell |
282,753
-23,466
| -8% | -$1.06M | ﹤0.01% | 2217 |
|
|
2021
Q4 | $18.3M | Buy |
306,219
+29,288
| +11% | +$2.35M | ﹤0.01% | 2012 |
|
|
2021
Q3 | $23.8M | Sell |
276,931
-25,026
| -8% | -$2.51M | ﹤0.01% | 1836 |
|
|
2021
Q2 | $33.6M | Buy |
301,957
+25,218
| +9% | +$2.42M | ﹤0.01% | 1625 |
|
|
2021
Q1 | $30.8M | Buy |
276,739
+66,372
| +32% | +$8.73M | ﹤0.01% | 1586 |
|
|
2020
Q4 | $22.3M | Buy |
210,367
+10,746
| +5% | +$1.43M | ﹤0.01% | 1649 |
|
|
2020
Q3 | $27.8M | Buy |
199,621
+17,753
| +10% | +$3.7M | 0.01% | 1285 |
|
|
2020
Q2 | $58.8M | Buy |
181,868
+41,496
| +30% | +$6.66M | 0.01% | 812 |
|
|
2020
Q1 | $12.5M | Buy |
140,372
+27,782
| +25% | +$1.71M | ﹤0.01% | 1601 |
|
|
2019
Q4 | $4.46M | Buy |
112,590
+4,866
| +5% | +$146K | ﹤0.01% | 2527 |
|
|
2019
Q3 | $2.65M | Buy |
107,724
+7,761
| +8% | +$236K | ﹤0.01% | 2770 |
|
|
2019
Q2 | $3.53M | Buy |
99,963
+5,695
| +6% | +$226K | ﹤0.01% | 2614 |
|
|
2019
Q1 | $4.22M | Buy |
94,268
+10,593
| +13% | +$534K | ﹤0.01% | 2428 |
|
|
2018
Q4 | $4.02M | Buy |
83,675
+10,414
| +14% | +$633K | ﹤0.01% | 2349 |
|
|
2018
Q3 | $4.89M | Buy |
73,261
+2,283
| +3% | +$127K | ﹤0.01% | 2371 |
|
|
2018
Q2 | $3.34M | Buy |
70,978
+3,870
| +6% | +$213K | ﹤0.01% | 2557 |
|
|
2018
Q1 | $3.79M | Sell |
67,108
-2,361
| -3% | -$128K | ﹤0.01% | 2413 |
|
|
2017
Q4 | $3.44M | Buy |
69,469
+6,583
| +10% | +$408K | ﹤0.01% | 2442 |
|
|
2017
Q3 | $4.78M | Buy |
62,886
+14,248
| +29% | +$1.06M | ﹤0.01% | 2232 |
|
|
2017
Q2 | $4.58M | Buy |
48,638
+1,958
| +4% | +$167K | ﹤0.01% | 2203 |
|
|
2017
Q1 | $3.71M | Buy |
46,680
+5,170
| +12% | +$412K | ﹤0.01% | 2286 |
|
|
2016
Q4 | $3.46M | Buy |
41,510
+1,138
| +3% | +$103K | ﹤0.01% | 2297 |
|
|
2016
Q3 | $4.51M | Buy |
40,372
+577
| +1% | +$63.7K | ﹤0.01% | 2031 |
|
|
2016
Q2 | $4.41M | Sell |
39,795
-325
| -0.8% | -$39.5K | ﹤0.01% | 1999 |
|
|
2016
Q1 | $4.19K | Buy |
40,120
+3,744
| +10% | +$289K | ﹤0.01% | 1976 |
|
|
2015
Q4 | $2.93M | Buy |
36,376
+735
| +2% | +$58.5K | ﹤0.01% | 2224 |
|
|
2015
Q3 | $2.47M | Buy |
35,641
+649
| +2% | +$56.5K | ﹤0.01% | 2298 |
|
|
2015
Q2 | $3.43M | Buy |
34,992
+6,360
| +22% | +$680K | ﹤0.01% | 2157 |
|
|
2015
Q1 | $2.8M | Buy |
28,632
+990
| +4% | +$95.9K | ﹤0.01% | 2223 |
|
|
2014
Q4 | $3.04M | Buy |
27,642
+395
| +1% | +$48.3K | ﹤0.01% | 2141 |
|
|
2014
Q3 | $3.22M | Buy |
27,247
+2,173
| +9% | +$271K | ﹤0.01% | 2051 |
|
|
2014
Q2 | $3.25M | Buy |
25,074
+6,476
| +35% | +$764K | ﹤0.01% | 2079 |
|
|
2014
Q1 | $2.97M | Buy |
18,598
+1,771
| +11% | +$254K | ﹤0.01% | 2103 |
|
|
2013
Q4 | $2.34M | Buy |
16,827
+2,531
| +18% | +$253K | ﹤0.01% | 2201 |
|
|
2013
Q3 | $1.42M | Buy |
14,296
+1,119
| +8% | +$93.8K | ﹤0.01% | 2377 |
|
|
2013
Q2 | $504K | Buy |
+13,177
| New | +$399K | ﹤0.01% | 2874 |
|
Other funds holding INO
VCM
BCM
ACM
EP
Geode Capital Management's INO Position: Q1 2026 in Review
Geode Capital Management increased its Inovio Pharmaceuticals (INO) stake by 4.2% in Q1 2026, buying an estimated $52.9K and bringing the position to 801,504 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3252.
Geode Capital Management first reported a position in INO in Q2 2013 and has held it in 52 quarters since. The position peaked at $58.8M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.
- Geode Capital Management held 801,504 shares of Inovio Pharmaceuticals worth $1.4M as of Q1 2026.
- Geode Capital Management bought 32,148 Inovio Pharmaceuticals shares in Q1 2026, an estimated $52.9K.
- Inovio Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3252 holding.
- Geode Capital Management first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Geode Capital Management's Inovio Pharmaceuticals position peaked at $58.8M in Q2 2020.
- 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.